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Intestinal PPARγ signalling is 
required for sympathetic nervous 
system activation in response to 
caloric restriction
Kalina Duszka1,2, Alexandre Picard2, Sandrine Ellero-Simatos3, Jiapeng Chen1, 
Marianne Defernez4, Eeswari Paramalingam1, Anna Pigram4, Liviu Vanoaica2, 
Cécile Canlet5,6,7, Paolo Parini8, Arjan Narbad4, Hervé Guillou3, Bernard Thorens1,2 & 
Walter Wahli1,2,3
Nuclear receptor PPARγ has been proven to affect metabolism in multiple tissues, and has received 
considerable attention for its involvement in colon cancer and inflammatory disease. However, its 
role in intestinal metabolism has been largely ignored. To investigate this potential aspect of PPARγ 
function, we submitted intestinal epithelium-specific PPARγ knockout mice (iePPARγKO) to a two-
week period of 25% caloric restriction (CR), following which iePPARγKO mice retained more fat than 
their wild type littermates. In attempting to explain this discrepancy, we analysed the liver, skeletal 
muscle, intestinal lipid trafficking, and the microbiome, none of which appeared to contribute to the 
adiposity phenotype. Interestingly, under conditions of CR, iePPARγKO mice failed to activate their 
sympathetic nervous system (SNS) and increase CR-specific locomotor activity. These KO mice also 
manifested a defective control of their body temperature, which was overly reduced. Furthermore, the 
white adipose tissue of iePPARγKO CR mice showed lower levels of both hormone-sensitive lipase, and 
its phosphorylated form. This would result from impaired SNS signalling and possibly cause reduced 
lipolysis. We conclude that intestinal epithelium PPARγ plays an essential role in increasing SNS 
activity under CR conditions, thereby contributing to energy mobilization during metabolically stressful 
episodes.
Caloric restriction (CR) increases life span and improves the health of diverse species under laboratory condi-
tions1,2. Lifelong CR can extend lifespans by up to 50% in rodents, with lesser effects should CR commence later 
in life3. CR both delays and slows-down the progression of age-related diseases, including neurodegenerative, 
autoimmune and cardiovascular disease, type 2 diabetes, and cancer4. However, the molecular mechanisms that 
underlie these beneficial effects remain unknown.
Peroxisome proliferator activated receptor gamma (PPARγ ) is a member of the PPAR nuclear receptor sub-
family that is primarily known for its insulin sensitizing properties and role as a master regulator of adipogenesis5. 
PPARγ also modulates a wide range of processes including cellular proliferation, differentiation, glucose and lipid 
metabolism, and inflammation5–9. PPARγ is highly expressed in adipocytes and in the gastrointestinal (GI) tract, 
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and is expressed at lower levels in the pancreas, liver, and kidney. In the GI tract, PPARγ is present at a relatively 
high level in the duodenum, and at lower levels throughout the small intestine, reaching its peak expression in the 
proximal colon, before decreasing again in the distal colon10–12. PPARγ expression and activity are induced in the 
gut by multiple nutrient species, most notably fatty acids and their metabolites, but also by glutamine, curcumin, 
capsaicin, ginsenosides, vitamin E, and selenium, all of which have anti-inflammatory properties13. Importantly, 
bacterial metabolites and bacterial by-products such as butyrate14,15, H2O216, and LPS17, also activate PPARγ .
To date, the role of PPARγ in the gastrointestinal tract has, in the main, been restricted to the study of inflam-
mation and cancer, which has led to the identification of PPARγ as a promising therapeutic target in colon cancer. 
PPARγ inhibits the development of colorectal cancer by decreasing cellular proliferation18–20, increasing cell dif-
ferentiation18,21, inducing apoptosis18,19,22–24, and by inhibiting angiogenesis25. PPARγ agonists also mitigate the 
symptoms of inflammatory bowel disease, reduce inflammation, and are effective in multiple models of ulcerative 
colitis26–35, as well as in Crohn’s disease36. Moreover, PPARγ is responsible for the selective killing of bacteria asso-
ciated with IBD37. Thus, there is a dynamic balance that involves reciprocal interactions between PPARγ and gut 
microbiota, with PPARγ both activated by bacteria, and capable of regulating the composition of that intestinal 
microbiota.
The essential contribution of PPARγ to metabolic regulation in multiple organs suggests potential roles in 
the intestine other than those already described in inflammation and cancer. We therefore challenged intestinal 
epithelium-specific PPARγ knockout (iePPARγ KO) mice with several metabolic stimuli. Here, for the first time, 
we provide evidence for a connection between CR and intestinal PPARγ . Under conditions of CR, intestinal epi-
thelial PPARγ increases sympathetic nervous system (SNS) activity and promotes the use of stored fat.
Results
Intestinal PPARγ regulates body adiposity in mice subjected to CR. An intestinal epithelium-spe-
cific PPARγ knockout mouse was generated by crossing floxed Pparγ (PPARγfl/fl)38 mice with mice expressing 
the Cre recombinase transgene under the control of the villin promoter (VillinCre+ )39. The offspring, PPARγ 
VillinCre+ mice, carry a targeted disruption of Pparγ in their intestinal epithelium; these animals, denoted ieP-
PARγ KO mice, were used in parallel with littermate controls (PPARγ VillinCre-), or wild-type (WT) mice with 
the same genetic background. Gene deletion was specific to the gastrointestinal tract (see Supplementary Fig. S1), 
with successful disruption of Pparγ resulting in a loss of PPARγ protein expression (Supplementary Fig. S1). 
A very low level of Pparγ deletion was also apparent in the kidney (Supplementary Fig. S1), agreeing with the 
expression of villin in the epithelial cells of proximal tubules39–41. Despite this, we could not detect decreased 
Pparγ mRNA levels in total RNA samples derived from the kidney (Supplementary Fig. S1). No obvious pheno-
types were evident in the iePPARγ KO mice during ad libitum feeding, i.e. there were neither differences in body 
weight nor the size of internal organs when comparing iePPARγ KO and WT mice.
Mice were then exposed to CR, which entailed a 25% reduction in daily food intake for two weeks. As a result 
of CR, both the iePPARγ KO and WT mice lost close to 20% of their body weight (Fig. 1a). Despite having a sim-
ilar body weight after CR, the remaining body fat content of iePPARγ KO CR mice was significantly higher than 
that of WT CR mice (Fig. 1b). This finding was confirmed by an increased percentage of lean mass identified 
in WT animals compared to iePPARγ KO mice (Fig. 1c), that was not seen in animals fed ad libitum. EchoMRI 
results were confirmed by the weights of white adipose tissue (WAT) pads. Epididymal and subcutaneous dorsal 
WAT pads were significantly heavier in iePPARγ KO CR mice than in WT CR mice (Fig. 1d, expressed as relative 
(% body weight), and absolute values (gram), Supplementary Fig. S2). Histological examination of epididymal 
adipocytes showed generally smaller adipocytes in CR versus ad libitum mice (Fig. 1e–h). Furthermore, adipo-
cytes from iePPARγ KO CR mice were bigger than those from WT CR mice, suggesting reduced lipid release 
during CR (Fig. 1g,h). However, the adipocytes of iePPARγ KO CR mice were smaller than their counterparts 
fed ad libitum, indicating that CR-triggered lipid release still took place in iePPARγ KO CR adipocytes, but to a 
significantly lesser degree than in WT CR adipocytes. This difference in adiposity was reflected by higher plasma 
leptin levels (Fig. 1i) in CR iePPARγ KO mice vs. CR WT mice. We concluded that iePPARγ KO mice retain more 
body fat than WT mice during CR-stimulated energy mobilization.
As a control, we verified that there was no unscheduled deletion of Pparγ in epididymal, subcutaneous 
abdominal, as well as subcutaneous dorsal adipose tissues (Supplementary Fig. S2). Theoretically, gene deletion 
could occur should the villin promoter be induced under CR stress.
Next we assayed whether the difference in adipose tissue mass between iePPARγ KO and WT mice was pre-
served after resumption of a normal dietary regimen for two additional weeks. During this period, the animals 
regained weight, to levels comparable to those recorded prior to CR (Fig. 1j), with percent body fat also compa-
rable to pre CR levels in both genotypes (Fig. 1k). Hence, the difference in body fat content in CR conditions was 
reversible for both iePPARγ KO and WT mice.
Expression of iePPARγKO adiposity phenotype under diverse, prolonged, metabolic 
stresses. We then tested whether the adiposity phenotype of iePPARγ KO mice could be triggered by 
other situations involving metabolic stress. Mice were given an ad libitum no-sucrose diet (NSD; sucrose 
free diet), or a high-fat diet (HFD) for 6 months. The NSD resulted in an increased mass of subcutane-
ous and epididymal fat, with enhanced adipocyte size in iePPARγ KO mice compared to WT mice (Fig. 1l–n, 
Supplementary Fig. S2). However, total body mass and food intake were similar in both iePPARγ KO and WT 
mice (Supplementary Fig. S2). Both genotypes increased their fat mass to a comparable degree on the HFD 
(Fig. 1n, Supplementary Fig. S2). Consequently, we concluded that the iePPARγ KO adiposity phenotype only 
develops in situations of reduced energy availability.
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Figure 1. iePPARγKO mice lose less fat than WT mice when under caloric restriction (CR), or fed a no-
sucrose diet (NSD). WT and iePPARγ KO mice were submitted to CR and their body mass measured before 
and after the challenge (a). Percentage body fat (b) and lean mass (c) were assayed using EchoMRI, with the 
pad weights of white adipose tissue (WAT) recorded (n = 10–14 mice) (d). Adipocyte size was determined by 
histological analyses for mice fed ad libitum (e) and after CR (g). The average cell surface area of 50 cells per 
histologic section (n = 4–5 sections) was determined for mice fed ad libitum (f) and after CR (h). The plasma 
concentration of leptin was measured for mice fed ad libitum and after CR (i); n = 11–14 mice. Body weight 
(j) and the percentage of body fat (k) were measured in mice fed ad libitum, in mice after 2 weeks of CR, and 
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Metabolic gene expression was unaltered in the WAT of iePPARγKO CR mice. Next we compared 
changes in gene expression in the epididymal WAT of iePPARγ KO CR mice vs. WT CR mice. As CR stimulates 
lipolysis, and the release of energy stored in adipocytes, we measured the expression of genes associated with lipid 
metabolism. Acetyl-CoA carboxylase (Acc) expression increased under CR compared to ad libitum conditions. 
However, there were no significant differences in the expression of genes related to metabolism, the uncoupling 
of oxidative phosphorylation, or autophagy, when comparing WAT tissue derived from iePPARγ KO CR vs. WT 
CR mice (Supplementary Fig. S3).
Liver and muscle are not significantly affected by CR in iePPARγKO mice. We then analysed 
two other metabolic organs, the liver and skeletal muscle, for any differences between iePPARγ KO vs. WT 
mice under conditions of CR. We found no differences in terms of either liver weight or glycogen content 
(Supplementary Fig. S3). The expression of major genes associated with lipid metabolism, lipid transport, glyco-
gen synthesis (Gys2), and gluconeogenesis were all comparable except for Pparα and fructose-bisphosphatase 1 
(Fbp1), which were upregulated in iePPARγ KO CR vs. WT CR mice (Supplementary Fig. S3).
During prolonged fasting, muscles are used as an energy supply, leading to sarcopenia. We analysed muscle 
mass and found that after the 2-week CR diet, the weight of the soleus, gastrocnemius, and tibialis anterior mus-
cles did not differ between iePPARγ KO and WT mice (Supplementary Fig. S3). None of the tested genes involved 
in muscle fibres, autophagy, and metabolism, showed differential expression in iePPARγ KO CR vs. WT CR mice 
in the soleus and tibialis anterior muscles (Supplementary Fig. S3). Thus, the liver and muscles are not signifi-
cantly affected in CR iePPARγ KO mice. We concluded that CR selectively affects adipose tissue in iePPARγ KO 
mice.
The iePPARγKO adiposity phenotype is neither the result of altered intestinal lipid uptake nor 
lipid transport. Since the phenotype observed in iePPARγ KO mice is caused by the deletion of Pparγ in the 
intestinal epithelium, we then investigated CR-induced changes in the gut. We observed that PPARγ protein levels 
were similar between ad libitum and CR conditions (Fig. 1o). We then assayed PPARγ transcriptional activity by 
measuring the expression of several PPARγ target genes (Pparα, Cd36, Fiaf, Scd1). While there were no differ-
ences between WT and iePPARγ KO mice under ad libitum feeding conditions, there was a higher expression 
under CR conditions in WT animals compared to iePPARγ KO (Fig. 2a). This result suggests that in the intestine, 
PPARγ is activated by CR. We also found that the expression of the intestinal hormone genes Cck, Gip, Xenin, 
Tac1, and Glp1, were up-regulated in iePPARγ KO CR vs. WT CR mice. Consistently, plasma GLP-1 was signif-
icantly increased, while there was only a trend for increased PYY and GIP in the iePPARγ KO CR compared to 
WT CR mice (Fig. 2b). In contrast to hormones, the expression of several genes connected with lipid metabolism 
were upregulated in WT mice in response to CR, but were unaffected in the iePPARγ KO epithelium (Acsl3, Acot4, 
and Vldlr; Fig. 2a), again demonstrating PPARγ activation under conditions of CR. This suggested a possible 
differential intestinal lipid uptake in iePPARγ KO CR vs. WT CR mice. However, a lipid oral load test revealed 
no differences in the plasma lipid concentration between iePPARγ KO CR and WT CR mice at any time point 
after oil gavage (Fig. 2c). Furthermore, a direct bomb bomb calorimetry measurement, which assays leftover 
energy in mouse faeces, showed no differences between the two groups of mice under CR conditions (Fig. 2d). 
In addition, the quantity of faecal matter generated by iePPARγ KO CR and WT CR mice was comparable 
(Supplementary Fig. S4).
To further investigate whether nutrient uptake was altered in iePPARγ KO CR mice, we assayed the levels of 
various plasma metabolites (see Supplementary Table S1). Triglycerides, cholesterol, and glucose levels differed 
between the ad libitum fed, CR, and NSD groups. However, these levels were comparable in iePPARγ KO and WT 
mice under all experimental conditions (ad libitum, CR, and NSD). Similarly, we found no genotype-specific 
differences in plasma lipoprotein triglyceride content, suggesting that there is no difference between WT and 
iePPARγ KO mice in terms of either hepatic lipoprotein loading or lipid distribution to peripheral organs. 
Furthermore, levels of plasma lipase activity were unaltered in iePPARγ KO mice feeding ad libitum vs. CR con-
ditions (Supplementary Fig. S4), suggesting no impact on lipid uptake from plasma by the peripheral organs. We 
concluded that there is no change in either lipid uptake in the GI tract, or its redistribution to peripheral organs 
in iePPARγ KO mice, and that the iePPARγ KO CR adiposity phenotype does not result from the increased uptake 
of dietary fat.
The microbiome does not impact the iePPARγKO CR adiposity phenotype. As the expression of 
inflammatory and antibacterial genes are regulated in the GI tract in response to CR (K. Duszka, in preparation), 
we next tested whether their expression could also be regulated in the intestines of iePPARγ KO mice under 
in mice after 2 weeks of resumption of normal feeding (n = 8–10 mice). Histological sections from the WAT of 
mice on a no-sucrose diet (NSD) were analysed (l), and the average adipocyte surface area measured (m). WAT 
pad weights were measured in mice on a NSD, and a high fat diet (HFD), and are represented as a percentage 
of body weight (n = 6–16 mice) (n). PPARγ protein levels were assayed by western blot (o), using tissue derived 
from intestinal epithelium scrapings of ad libitum and CR mice. The signals were quantified, with statistical 
significance verified using the Student’s t-test; data are presented as means with STD, p = 0.3. All data besides 
panel o are shown as mean values ± SEM error bar. For panels (f,h,m,j,k,o), the Student’s t test was performed, 
p < 0.05. For the remainder of the graphs, one-way ANOVA with a Bonferroni post-hoc test was applied. The 
following symbols #,##,*,***, correspond to statistically significant differences for the following data sets: WT vs. 
WT CR; KO vs. KO CR; WT CR vs. KO CR; and WT NSD vs. KO NSD, respectively.
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Figure 2. Intestinal lipid uptake and microbiota do not contribute to the iePPARγKO caloric restriction 
(CR) adipose tissue phenotype. The relative mRNA expression levels of metabolism-associated genes and 
intestinal hormones were assayed by RT-qPCR in the intestinal epithelium of WT and iePPARγ KO mice fed 
ad libitum or under CR (n = 10–12 mice) (a). Plasma concentrations of GIP, PYY and GLP-1 were measured 
for WT and iePPARγ KO mice fed ad libitum and after CR (b); n = 7–9. WT CR mice and iePPARγ KO CR 
mice were gavaged with oil, and their blood triglyceride (TG) concentrations measured at the indicated time 
points (n = 8 mice) (c). The energy content of faeces from WT CR and iePPARγ KO CR mice was measured 
using direct calorimetry (n = 9 mice) (d). The relative mRNA expression levels of inflammatory factors and 
antibacterial and antiviral peptides were quantified in the intestinal epithelium of WT and iePPARγ KO CR mice 
(n = 10–12 mice) (e). Murine faecal microbiota composition and metabolites were analysed by sequencing  
(f) and by NMR (g), and the two data sets jointly analysed (h). The statistical difference in plasma TG and faecal 
energy load was assessed by the Student’s t-test. Gene expression data were analysed using one-way ANOVA 
fallowed by Bonferroni post-hoc test. Symbols #, # #, and *, correspond to statistically significant differences 
between WT and WT CR data, KO and KO CR data, and WT CR and KO CR data, respectively. Error bars 
depict the standard error.
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CR conditions. We found no difference in the expression of inflammatory factor genes for WT vs. iePPARγ KO 
mice. However, compared to WT mice, the iePPARγ KO mouse intestine showed a much weaker down-regulation 
of antibacterial and antiviral peptide gene expression (Reg3β, Reg3γ, IRF7, NOS2, Oas1a) in response to CR 
(Fig. 2e). Since antibacterial and antiviral peptides influence the composition of the gut microbiota, and intes-
tinal bacteria modify body fat content42–46, we then performed molecular profiling of the faecal microbiota, 
which revealed significant differences in the bacterial composition of WT vs. iePPARγ KO mice fed ad libitum 
(Fig. 2f, Supplementary Fig. S4, and Supplementary Table S2). Interestingly, CR triggered a strong shift in the 
faecal microbiota resulting in a similar final microbiota composition in both WT and iePPARγ KO mice. These 
data indicated that the effects of CR on microbiota were stronger than those caused by PPARγ deletion (Fig. 2f). 
We predicted that these changes would be reflected in faecal metabolites, which we then analysed using nuclear 
magnetic resonance (NMR). Confirming the sequencing results, there were differences in the faecal metabolite 
profiles of WT vs. iePPARγ KO mice fed ad libitum (e.g. lower levels of lactate and succinate in iePPARγ KO 
mice; data not shown). These differences disappeared under conditions of CR, which triggered a large shift in the 
metabolite profiles in both strains (Fig. 2g).
Integrating the sequencing and NMR datasets using canonical correlation confirmed that CR had a much 
stronger effect than intestinal PPARγ deletion on gut microbiota (Fig. 2h). In contrast to the significant differ-
ences in microbiota composition between WT and iePPARγ KO mice fed ad libitum, there were no significant 
differences in either bacterial composition or faecal metabolic profiles in WT vs. iePPARγ KO CR mice, sug-
gesting that the gut microbiota was most likely not an important determinant of the iePPARγ KO CR adiposity 
phenotype.
iePPARγKO mice fail to adjust their body temperature and locomotor activity appropri-
ately during CR. Next we tested whether the iePPARγ KO CR adiposity phenotype was caused by defec-
tive regulation of whole body metabolism by measuring metabolic parameters and recording physical activity 
using indirect calorimetry. Under CR, mice of both genotypes decreased their respiratory exchange ratio val-
ues (Supplementary Fig. S4), reflecting the switch from carbohydrate to lipid as a main energy source. WT 
mice responded to CR by decreasing VCO2, although changes to VO2 levels were not statistically significant 
(Supplementary Fig. S4). We detected slight differences in CO2 production between iePPARγ KO and WT mice 
only in ad libitum conditions, but there were no data to suggest differences in either energy usage or its dissi-
pation between CR WT and CR iePPARγ KO mice. Animals of both genotype decreased their heat production 
upon CR (Supplementary Fig. S4), confirming previous findings for body temperature adjustments to low energy 
availability47. Even though we did not detect differences in heat production between WT and iePPARγ KO mice 
using indirect calorimetry, telemetry revealed decreased body temperatures in iePPARγ KO CR compared to WT 
CR mice (Fig. 3a). Importantly, we neither observed differences in brown adipose tissue (BAT) weight (Fig. 3b), 
nor Ucp1 expression (Fig. 3c) when comparing iePPARγ KO CR and WT CR mice. Furthermore, Pparγ was nor-
mally expressed in the BAT of iePPARγ KO CR mice, consistent with an absence of Pparγ gene deletion (Fig. 3c, 
Supplementary Fig. S4).
Mice showed increased locomotor activity at night compared to day-time (Fig. 3d). Under conditions of 
CR, WT mice increased their activity with lesser day/night differences compared to mice feeding ad libitum. 
Movement counts of iePPARγ KO CR mice revealed that their mobility was significantly lower than that of WT 
CR mice and was comparable to that of animals fed ad libitum. To evaluate whether this difference in physical 
activity reflected differences in hunger perception, or a decreased motivation to eat, we measured how fast CR 
mice reached for food after daily chow portion delivery. As the duration of CR increased, the time taken for all 
mice to initiate food intake decreased (Fig. 3e), with no difference between iePPARγ KO CR and WT CR mice. 
Furthermore, the expression of hunger-related genes in mouse hypothalami under CR were similar in iePPARγ KO 
and WT mice (Supplementary Fig. S4). Thus, the perception of hunger and the drive to feed do not appear to 
underlie the differences in physical activity between iePPARγ KO CR and WT mice.
We subsequently verified that there was no hypothalamic Pparγ deletion in iePPARγ KO mice under 
CR, given that stress could promote ectopic expression of the villin promoter, resulting in a central nerv-
ous system-associated phenotype. We confirmed no difference in Pparγ expression compared to WT mice 
(Supplementary Fig. S4), with expression unaffected in the hypothalamus of iePPARγ KO mice, and a reproduci-
ble absence of Pparγ deletion in the hypothalamus (Supplementary Fig. S4).
iePPARγKO mice show dysfunctional sympathetic nervous system (SNS) stimulation dur-
ing CR. In seeking a connection between lipolysis stimulation, physical activity, and body temperature, 
we then recorded autonomic nervous system activity to evaluate the main body function control centre. 
Interestingly, CR increased SNS firing in WT mice but not in iePPARγ KO mice (Fig. 3f,g). SNS sympathetic 
activity remained at comparable levels in iePPARγ KO mice irrespective of CR or ad libitum feeding conditions. 
Furthermore, parasympathetic signalling (PSNS) was upregulated in iePPARγ KO CR compared to WT CR mice 
(Supplementary Fig. S4), which is in line with their less active behaviour.
As the SNS stimulates β -adrenergic signalling in adipocytes, which promotes lipolysis48, we then deter-
mined levels of hormone-sensitive lipase (HSL) and activated HSL (Phospho-HSL) in epididymal WAT. 
Although we observed no differences in Hsl mRNA expression levels between WT CR and iePPARγ KO CR mice 
(Supplementary Fig. S3), there were decreased levels of HSL and phosphorylated HSL (p-HSL) in the WAT of 
iePPARγ KO CR vs. WT CR (Fig. 3i,k). These differences were not detected in mice fed ad libitum (Fig. 3h,j). 
These results imply that iePPARγ KO mice fail to adjust their autonomic nervous system activity in response to 
CR, which manifests as deficient lipolysis in their WAT.
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Figure 3. iePPARγKO mice subject to caloric restriction (CR) show altered body temperature, locomotor 
activity, sympathetic nervous system (SNS) signalling, and WAT lipase expression. Body temperature (n = 7 
mice) was recorded before and after CR (a). BAT was dissected from ad libitum and CR mice with weight  
(b) and gene expression profiles (c) subsequently measured. Mice locomotor activity was recorded for ad 
libitum fed mice, and after 14 days of CR (n = 12 mice per group) (d). During the daily food portion delivery, 
the time from when the pellets were placed in the cage to the initiation of feeding was measured each day for 
the 2-week CR protocol (n = 8–13 mice) (e). The frequency of sympathetic nerve firing in WT and iePPARγKO 
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Discussion
Investigating the role of PPARγ in the intestine, we observed that iePPARγ KO mice retained more fat than WT 
mice when subject to a two-week period of CR. Since iePPARγ KO and WT mice both lost a substantial portion of 
their body fat during this period, we propose that the higher WAT mass in iePPARγ KO mice after CR results from 
diminished fat loss, rather than from increased fat accumulation. Supporting this hypothesis, our data showed 
that iePPARγ KO mice manifested no signs of either aberrant lipid uptake or delivery to peripheral tissues, but 
instead exhibited decreased levels of a key lipolytic enzyme, HSL, and its active form p-HSL, in WAT. From these 
data we deduced that the iePPARγ KO mouse adiposity phenotype results from an altered release of lipids stored 
in WAT during CR-stimulated energy mobilization. Importantly, the SNS is a major regulator of lipolysis via 
β -adrenergic receptor activation49. Our observations suggest that lipolysis activation is impaired in iePPARγ KO 
mice due to a failure in the SNS response to CR (Fig. 4). Interestingly, the adiposity phenotype is similar for ieP-
PARγ KO mice subject to either CR or a NSD, suggesting that some of the benefits of CR might be replicated when 
the nutritional composition of the diet is changed.
Based on the plasma lipoprotein lipid content, liver weight, and hepatic gene expression data, we conclude that 
liver lipid metabolism is not affected in iePPARγ KO mice and is unlikely to contribute to the adiposity pheno-
type. Liver glycogen release upon fasting is stimulated by the SNS50. However, glycogen stores are activated and 
depleted in advance of fat deposits, which most likely explains why we saw no differences in these stores when 
comparing WT CR and iePPARγ KO CR mice (i.e. after 2 weeks of CR).
Other than the intestinal epithelium, the villin gene is also selectively expressed in the kidney, in the epi-
thelium of proximal tubules41. There are no reports showing villin expression in the juxtaglomerular cells that 
produce and store renin. Thus, despite our observation of a very limited deletion of Pparγ in the kidney, it is 
extremely unlikely that a renin-angiotensin-aldosterone system failure would contribute to the iePPARγ KO adi-
posity phenotype.
Applying the 2-week CR protocol, we did not observe differences in intestinal epithelium PPARγ protein lev-
els. However, the stimulation of PPARγ target genes indicated an increased transcriptional activity of the receptor 
during CR, most likely induced by an increase in its endogenous ligands. Under CR, WT mice showed elevated 
locomotor activity, which is interpreted as natural food-seeking behaviour. Surprisingly, iePPARγ KO mice did 
not show this basic behavioural response to CR. We investigated several possible reasons for this phenotype. First, 
we tested muscular integrity, since iePPARγ KO mice might utilize muscle protein as a source of energy under 
conditions of CR, which could lead to sarcopenia and diminished locomotive function. However, this was ruled 
out based on skeletal muscle weight and gene expression data. Second, we tested hunger perception and the moti-
vation to eat. We could find no differences in hypothalamic gene expression, or the time taken to approach food 
during daily feedings in iePPARγ KO CR vs. WT CR mice, demonstrating that neither hunger perception, nor 
the drive to feed were altered in iePPARγ KO mice under CR. Third, we tested activation of the SNS to mobilize 
energy stores under stress situations. A primitive SNS-related fight-or-flight response is associated with increased 
mobility to locate food and ensure survival. Critically, the iePPARγ KO mice showed a disturbed SNS activation in 
response to hunger and manifested higher parasympathetic activity compared to WT mice. In addition, their body 
temperature was significantly lower than that of WT mice. Thus, a decreased perception of energy deprivation 
might be linked to reduced fat store depletion in iePPARγ KO mice. The lack of SNS stimulation in iePPARγ KO 
CR mice and their higher PSNS activity most likely explains why they are less active than WT CR mice.
Lipolysis in adipose tissue is activated by a cascade of phosphorylation events derived from a SNS-stimulated 
activation of β -adrenergic receptors, leading to lipase activation48. Decreased levels of HSL, as well as p-HSL in 
the WAT of iePPARγ KO vs. WT mice under conditions of CR, correlated with reduced SNS activity and the ieP-
PARγ KO adiposity phenotype.
Looking for possible traits to link the intestine and autonomic nervous system, we considered extrinsic 
bacteria-derived, as well as intrinsic, host-specific causes. As bacterial-derived acetate affects the activation of the 
parasympathetic nervous system51, we determined the metabolite composition of mice faeces. However, we could 
not observe any differences between metabolite generation in WT vs. iePPARγ KO mice, including acetates. As a 
possible host-specific cause of the adiposity phenotype, we then considered intestinal hormones that can influ-
ence SNS activity and signalling to the brain52,53. Again, we could not demonstrate a direct link between intestinal 
PPARγ and the SNS. However, the observed PPARγ -related modulation of plasma concentrations of intestinal 
hormones suggests that PPARγ could influence the SNS via intestinal hormone production. This will be the focus 
of a follow-up investigation.
Previously, Festuccia et al., proposed a link between PPARγ agonist administration and a tissue-specific reduc-
tion in BAT sympathetic activity54. Here we show, for the first time, that intestinal PPARγ signals the brain, and 
influences SNS activity. Our results suggest that PPARγ -triggered SNS activation may be WAT specific, as it 
neither affected BAT, skeletal muscle, nor liver. However, we observed at least two other phenotypes, a decreased 
body temperature, and reduced physical activity, suggesting the involvement of the central nervous system. 
mice fed ad libitum or subject to CR was measured (n = 6–7 mice) (f,g). Phospho-HSL, HSL, and β -tubulin 
protein levels in epididymal WAT were assayed by western blot for ad libitum (h) and CR (i) mice. Signals were 
quantified, with the data submitted to the Student’s t-test and presented as means with STD (j,k, respectively). 
Phospho-HSL activity was determined by normalisation of phospho-HSL protein expression relative to HSL 
protein expression. *p < 0.05. One-way ANOVA followed by the Bonferroni post-hoc test was used to compare 
the experimental groups from panels (a–f). Symbols #, # #, * correspond to statistically significant differences 
between the WT and WT CR datasets, KO and KO CR datasets, and WT CR and KO CR datasets, respectively. 
Data are presented as means ± SEM.
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Consequently, we anticipate that the iePPARγ KO mouse will emerge as a valuable model for research on the 
gut-brain axis.
Until now, there has been no clear link between PPARγ and CR in any tissue, although a connection has 
been previously suggested55–59. We now provide, for the first time, evidence to suggest that intestinal PPARγ is 
provoked by CR to activate the SNS, triggering a response to energy deprivation. The pathway through which 
intestinal PPARγ regulates sympathetic signalling remains obscure and is presently under investigation.
Materials and Methods
Animal care and experimental procedures. All experiments were performed in accordance with insti-
tutional guidelines and were approved by the Vaud Cantonal Authority in Switzerland, and by the Institutional 
Animal Care and Use Committee in Singapore. PPARγ floxVillinCre+ (iePPARγ KO) and PPARγ floxVillinCre- 
(WT) C57/Bl6/SV129 male mice were kept under a 12 h light/12 h dark cycle. Mice were fed a standard laboratory 
diet (Diet 3436; Provimi Kliba AG), and housed at a maximum of 5 animals per cage at 23 °C.
The experimental WT and iePPARγ KO mice were divided into two groups, the ad libitum and CR groups. 
Mice were housed one per cage to avoid fighting due to food restriction and to exclude the possibility of dominant 
males taking the majority of the available food. The CR animals were subject to a two-week CR that involved a 
reduction to 75% of their normal daily food intake. Food was provided daily 1–2 h before the dark phase. All 
animals had free access to water. Mouse body composition was measured under anaesthesia before and after 
the CR period using an EchoMRI whole-body composition analyzer (EchoMRI, Huston, TX, USA). Similarly, 
metabolic parameters (VO2, VCO2, heat, locomotor activity) were monitored before and after 2 weeks of CR 
using the Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments, Columbus, OH, 
USA). Body temperature was assayed using the DSI PhysioTel telemetry system (Data Sciences International, 
St. Paul, MN, USA). Mice were euthanized using CO2, with blood drawn by cardiac puncture. Blood was mixed 
with 2% aprotinin-EDTA (Sigma Aldrich, St. Louis, MO, USA), centrifuged for 10 min at 8,000 × g, and stored 
at − 20 °C. White adipose tissue fat pads, liver, and muscle weights were recorded. Tissues were snap frozen and 
stored at − 80 °C until use. The lipid oral load test was performed on CR mice by gavaging 200 μ l of oil. Blood was 
subsequently drawn from the tail at selected time points for analyses.
For the re-feeding experiments, mice were subject to CR for 2 weeks, followed by 2 weeks of free access to 
food. The weight and body composition of each mouse was measured before, and after 2 weeks of CR, and again 
after 2 weeks of re-feeding following CR.
For the diet/feeding experiments, 5-week-old mice were switched from standard chow to a sucrose-free diet 
(no-sucrose diet, NSD; #D12450K), or to a high fat diet from which 60% of energy requirements are derived 
from fat (#D12492). Both feeds were from Research Diets, Inc. (New Brunswick, NY, USA). Body-fat content was 
measured by EchoMRI, 16 weeks after the diet regimens began, with mice sacrificed one week later.
Western blotting. Upon harvest, adipose and duodenal tissues were immediately snap-frozen in liquid 
nitrogen. Tissues were stored at − 80 °C for subsequent lysis and western blot analyses with the indicated anti-
bodies. Adipose tissues were lysed in HNTG buffer comprising 50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glyc-
erol, 1% trition-X-100, supplemented with the cOmplete Mini Protease (Roche #4693159001) and PhosSTOP 
phosphatase inhibitor cocktails (Roche #4906837001). Tissues were homogenized using a TissueLyser (Qiagen). 
Lysates were then centrifuged at 18,000 × g, at 4 °C, for 20 min. The fat cake was removed prior to collecting the 
supernatant. Duodenal tissues were lysed in cold RIPA buffer (Thermofisher Scientific # 89900), again supple-
mented with the cOmplete™ Mini Protease (Roche #4693159001) and PhosSTOP phosphatase inhibitor cocktails 
(Roche #4906837001). Tissues were homogenized using a TissueLyser (Qiagen), then subject to centrifugation 
at 14,000 × g, at 4 °C, for 15 min, before collecting the supernatant. Comparable concentrations of total protein 
Figure 4. Model of adiposity regulation by intestinal PPARγ during caloric restriction. Transcriptional 
activity of PPARγ in enterocytes is changed during caloric restriction. This results in decreased expression of 
incretins and lower plasma level of GLP1. Incretins exported to the bloodstream signal to central nerve system 
(CNS) and affect the transmission of information to the autonomic nerve system (ANS). In response to shortage 
of nutrients sympathetic nerve system (SNS) is activated. SNS stimulates β -adrenergic receptors in adipocytes 
resulting in lipase phosphorylation and lipolysis activation.
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were loaded onto acrylamide/bis-acrylamide gels and, after their electrophoretic resolution, transferred to poly-
vinylidene fluoride membranes for detection with the indicated antibodies (anti Phospho-HSL (Ser660) antibody, 
Cell Signaling #4126; anti HSL antibody, Cell Signaling, #4107; anti beta-tubulin antibody, AbCam #ab6046; anti 
PPARγ antibody (H-100), Santa Cruz #sc-7196; and the anti U2AF65 antibody (H-300), Santa Cruz #sc-48804). 
Briefly, membranes were incubated with primary antibodies (used at a 1: 1,000 dilution for antibodies purchased 
from Cell Signaling, or a 1:200 dilution for reagents purchased from Santa Cruz) in 5% BSA/TBST, overnight. 
Horse radish peroxidase-conjugated secondary antibodies (Goat anti-rabbit IgG-HRP, Santa Cruz #sc-2054) 
(1: 5,000 dilution) were then added for 1 h. Membrane stripping was with Restore PLUS Western Blot Stripping 
Buffer (Thermofisher Scientific #46430). Western blots were developed using the Luminata Crescendo Western 
HRP Substrate (Millipore, #WBLUR0500), with signal detection by X-ray film.
Plasma and marker analyses. Plasma glucose, lipid, and cholesterol levels were measured using a Hitachi 
robot (Roche Diagnostics, Basel, Switzerland) according to the manufacturer’s instructions. Plasma lipase activity 
was analysed using the LPL activity Assay Kit (Roar Biomedical, Inc., New York, NY, USA). Plasma leptin and 
ghrelin concentrations were estimated using Bioplex (Luminex Corporation, Austin, TX, USA). Liver glycogen 
content was quantified using a glycogen assay kit (Sigma) according to the manufacturer’s instructions. Faecal 
energy load was measured using the IKA C200 (IKA Werke, Staufen, Germany) for direct bomb calorimetry. For 
plasma lipoprotein analyses, the lipoproteins in 2 μ L of plasma were separated by size-exclusion chromatography, 
followed by an online determination of total cholesterol and triglycerides TG as described previously60.
Autonomic nervous system activity. The firing rates of the thoracic branch of the vagal and sympathetic 
nerves were recorded along the carotid artery as described previously61,62. The sympathetic and vagal nerves, 
which lie close to the carotid artery, were dissected free of underlying tissues, to a distance of approximately 5 mm. 
The nerves were then covered with mineral oil to avoid dehydration and carefully placed on a pair of silver-wire 
recording electrodes (0.6-mm diameter). The electrodes were connected to a high-impedance probe, and the 
action potentials displayed and saved by computer after initial amplification through a low-noise amplifier (BIO 
amplifier, AD Instruments, Oxford, UK). Unipolar nerve activity was recorded continuously for 30 minutes using 
the LabChart 8 software (AD Instruments). Data were digitized with PowerLab 16/35 (AD Instruments). Signals 
were amplified 105 times and filtered using a 200/1000-Hz band pass filter. Firing rate analyses were performed 
using LabChart 8. All animal experimentation protocols were approved by the Vaud Cantonal Authority (author-
ization VD 2440), Switzerland, and by the Institutional Animal Care and Use Committee (authorization 2015/
SHS/1023) in Singapore. The Supplementary Methods provide details for qPCR, the sequencing of 16 S rDNA 
genes, 1 H NMR metabolomics, and data analyses.
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